Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ANIK
stocks logo

ANIK

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
28.88M
-5.64%
0.020
-166.67%
28.11M
+7.42%
0.000
-100%
29.50M
+4.54%
0.070
-153.85%
Estimates Revision
The market is revising Upward the revenue expectations for Anika Therapeutics, Inc. (ANIK) for FY2025, with the revenue forecasts being adjusted by 0.03% over the past three months. During the same period, the stock price has changed by 6.15%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.03%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-7.14%
In Past 3 Month
Stock Price
Go Up
up Image
+6.15%
In Past 3 Month
Wall Street analysts forecast ANIK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIK is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ANIK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIK is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.490
sliders
Low
16.00
Averages
16.00
High
16.00
Current: 9.490
sliders
Low
16.00
Averages
16.00
High
16.00
Barrington
Michael Petusky
Outperform
maintain
$15 -> $16
2025-11-06
Reason
Barrington
Michael Petusky
Price Target
$15 -> $16
2025-11-06
maintain
Outperform
Reason
Barrington analyst Michael Petusky raised the firm's price target on Anika Therapeutics to $16 from $15 and keeps an Outperform rating on the shares. The firm, which continues to think shares are "meaningfully undervalued," says "it appears that the company agrees" based on its recent decision to commence a $15M 10b5-1 share repurchase that it expects to complete by this June.
Barrington
Outperform
maintain
$20 -> $19
2025-05-12
Reason
Barrington
Price Target
$20 -> $19
2025-05-12
maintain
Outperform
Reason
Barrington Research
Michael Petusky
Buy
Maintains
$25 → $20
2025-03-13
Reason
Barrington Research
Michael Petusky
Price Target
$25 → $20
2025-03-13
Maintains
Buy
Reason
Barrington lowered the firm's price target on Anika Therapeutics to $20 from $25 and keeps an Outperform rating on the shares. Anika management reduced its previous adjusted EBITDA guidance for FY25, which had previously been forecast to be a double-digit margin but is now expected to be 8-10%, with pricing weakness in osteoarthritis pain management in the U.S. appearing to be the primary reason for the lowered outlook, the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Anika Therapeutics Inc (ANIK.O) is 52.72, compared to its 5-year average forward P/E of 202.80. For a more detailed relative valuation and DCF analysis to assess Anika Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
202.80
Current PE
52.72
Overvalued PE
855.72
Undervalued PE
-450.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-49.69
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
347.53
Undervalued EV/EBITDA
-446.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.47
Current PS
0.00
Overvalued PS
3.32
Undervalued PS
1.62
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

ANIK News & Events

Events Timeline

(ET)
2025-11-05
07:38:04
Anika announces submission of final PMA module for Hylofast cartilage repair.
select
2025-11-05
07:26:38
Anika Therapeutics Launches $15M Share Buyback Program Under 10b5-1 Plan
select
2025-11-05
07:26:14
Anika Therapeutics confirms its guidance for FY25
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
10-09Globenewswire
Reminder for Anika Investors: Bragar Eagel & Squire, P.C. Urges Anika Therapeutics Shareholders to Reach Out About Ongoing Investigation

  • Investor Alert: Bragar Eagel & Squire, P.C. is investigating potential claims against Anika Therapeutics, Inc. for possible violations of federal securities laws following a significant drop in stock price after the announcement of clinical trial results for Hyalofast.

  • Contact Information: Investors who suffered losses and wish to discuss their legal rights are encouraged to contact partners Brandon Walker or Marion Passmore at (212) 355-4648 or via email at investigations@bespc.com.

[object Object]
Preview
2.0
10-01NASDAQ.COM
Biotech Stocks Recover in After-Hours Trading Driven by Positive Sector Trends

  • Biotech Stocks Performance: Biotech stocks experienced strong after-hours gains, with notable rebounds from small-cap companies like Ovid Therapeutics, NeuroOne Medical, and PepGen, driven by positive sentiment following Pfizer's drug price cuts and investment in domestic manufacturing.

  • Ovid Therapeutics Update: Ovid Therapeutics saw a 7.69% increase in after-hours trading, supported by a recent Buy rating from Lucid Capital and a narrower quarterly loss, alongside a $7 million royalty sale agreement related to future revenues.

  • PepGen's Recent Surge: PepGen's stock rose 3.03% after-hours, continuing a volatile week with over 120% growth, attributed to positive Phase 2 trial results for its myotonic dystrophy treatment and a successful $100 million public offering.

  • Reviva Pharmaceuticals and Anika Therapeutics: Reviva Pharmaceuticals gained 5.81% after-hours following a significant intraday surge, while Anika Therapeutics rose 5.53% ahead of its upcoming earnings report, despite a quiet news cycle for both companies.

[object Object]
Preview
7.0
09-25Globenewswire
ANIKA (ANIK) UPDATE: Bragar Eagel & Squire, P.C. Launches Investigation into Anika Therapeutics, Inc. for the Benefit of Stockholders and Urges Investors to Reach Out to the Firm

  • Investor Alert: Bragar Eagel & Squire, P.C. is investigating potential claims against Anika Therapeutics, Inc. for possible violations of federal securities laws following a significant drop in stock price after the announcement of disappointing clinical trial results for Hyalofast.

  • Contact Information: Investors who suffered losses and wish to discuss their legal rights can contact Bragar Eagel & Squire partners Brandon Walker or Marion Passmore directly at (212) 355-4648 or via email at investigations@bespc.com.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Anika Therapeutics Inc (ANIK) stock price today?

The current price of ANIK is 9.49 USD — it has increased 0.21 % in the last trading day.

arrow icon

What is Anika Therapeutics Inc (ANIK)'s business?

Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.

arrow icon

What is the price predicton of ANIK Stock?

Wall Street analysts forecast ANIK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIK is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Anika Therapeutics Inc (ANIK)'s revenue for the last quarter?

Anika Therapeutics Inc revenue for the last quarter amounts to 27.82M USD, decreased -28.22 % YoY.

arrow icon

What is Anika Therapeutics Inc (ANIK)'s earnings per share (EPS) for the last quarter?

Anika Therapeutics Inc. EPS for the last quarter amounts to -0.16 USD, decreased -92.12 % YoY.

arrow icon

What changes have occurred in the market's expectations for Anika Therapeutics Inc (ANIK)'s fundamentals?

The market is revising Upward the revenue expectations for Anika Therapeutics, Inc. (ANIK) for FY2025, with the revenue forecasts being adjusted by 0.03% over the past three months. During the same period, the stock price has changed by 6.15%.
arrow icon

How many employees does Anika Therapeutics Inc (ANIK). have?

Anika Therapeutics Inc (ANIK) has 288 emplpoyees as of December 05 2025.

arrow icon

What is Anika Therapeutics Inc (ANIK) market cap?

Today ANIK has the market capitalization of 136.86M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free